How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,901 results for

Imiquimod

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1761. Invasive squamous cell carcinoma after treatment of carcinoma in situ with 5% imiquimod cream. (Abstract)

Invasive squamous cell carcinoma after treatment of carcinoma in situ with 5% imiquimod cream. Squamous cell carcinoma in situ has the potential to progress to invasive squamous cell carcinoma. This report presents two cases of punch biopsy-proven squamous cell carcinoma in situ, treated with once-daily application of 5% imiquimod cream for 6 weeks. Both patients developed moderate local inflammatory reactions during treatment. The first patient demonstrated clinical clearance of the scalp (...) lesion after treatment. Two months later, he re-presented with a subcutaneous nodule at the same site. Histology was consistent with recurrent squamous cell carcinoma. Five months following excision of the recurrent tumour, he presented with metastatic squamous cell carcinoma to a cervical lymph node. The second patient had low-grade chronic lymphocytic leukaemia and presented with squamous cell carcinoma in situ of the leg that failed to clear clinically after treatment with imiquimod. He presented

2006 Australasian Journal of Dermatology

1762. Treatment of atypical nevi with imiquimod 5% cream. Full Text available with Trip Pro

Treatment of atypical nevi with imiquimod 5% cream. 5% Imiquimod cream is a topical immune response modifier that has been used off-label to treat malignant melanocytic proliferations such as lentigo maligna. To our knowledge, imiquimod has not been previously used to treat atypical nevi (AN).Three patients each with 1 selected clinically AN were treated with imiquimod 5 nights per week for 12 weeks. The lesions were subsequently excised and sent for routine histologic and immunohistochemical (...) and for a surrogate marker of interferon alpha expression.Twelve weeks of imiquimod treatment failed to cause lesional resolution. A differential inflammatory response was observed between the AN and the congenital-like nevus. The character of the inflammatory infiltrate was similar to that observed with halo nevi. Uncertainties remain concerning imiquimod use for chemoprevention of AN, and the posttreatment histologic features may be misinterpreted as severe melanocytic atypia or melanoma.

2007 Archives of Dermatology

1763. Imiquimod treatment of anal intraepithelial neoplasia in HIV-positive men. Full Text available with Trip Pro

Imiquimod treatment of anal intraepithelial neoplasia in HIV-positive men. To evaluate the treatment of anal intraepithelial neoplasia (AIN) with the local immune response modifier imiquimod in human immunodeficiency virus (HIV)-positive men who have sex with men (MSM).Prospective, nonrandomized, open-label pilot study, with a mean follow-up time of 9(1/2) months.Dermatology department of a university hospital. Patients Twenty-eight consecutive HIV-positive MSM with histologically confirmed (...) perianal (n = 23) or intra-anal (n = 5) AIN. Intervention Overnight treatment with self-applied imiquimod cream (perianal AIN) or suppositories (intra-anal AIN) 3 times a week for 16 weeks.Response to treatment was documented using clinical, cytologic, and histologic criteria. Human papillomavirus (HPV) typing and HPV DNA load determination for the high-risk HPV types 16, 18, 31, and 33 were performed.Seventeen (61%) of all 28 patients included in the study and 17 (77%) of the 22 patients with AIN, who

2006 Archives of Dermatology

1764. Combined treatment with intratumoral injection of dendritic cells and topical application of imiquimod for murine melanoma. (Abstract)

Combined treatment with intratumoral injection of dendritic cells and topical application of imiquimod for murine melanoma. The maturation state of dendritic cells is one of the factors that affect their capacity to induce antigen-specific cytotoxic T lymphocytes. Topical cutaneous application of imiquimod can induce the maturation and migration of cutaneous dendritic cells.To evaluate the synergistic effect of topical application of imiquimod plus intratumoral injection of syngeneic bone (...) marrow-derived dendritic cells in the treatment of melanoma.For the B16F10 melanoma model, naive C57BL/6 mice were inoculated intradermally with 2x10(3) B16F10 melanoma cells in the right upper flank. Four groups (untreated control, dendritic cells alone, imiquimod alone and imiquimod plus dendritic cells) were included in the animal study, with five mice in each group. Tumour size was measured every 2 weeks, and histochemical and immunohistochemical staining carried out. ELISpot and PKH assays were

2007 Clinical & Experimental Dermatology

1765. First case series on the use of imiquimod for morphoea. (Abstract)

First case series on the use of imiquimod for morphoea. Morphoea is characterized by fibrosis, which is mediated by cytokines including transforming growth factor (TGF)-beta.Our objective was to use imiquimod 5% cream (Aldara), an inducer of interferon-gamma, known to inhibit TGF-beta, to treat morphoea.Patients with morphoea were treated with imiquimod and evaluated during their follow-up visits to 6 months.The dyspigmentation, induration and erythema of 12 patients with morphoea lesions (...) improved. The histology of the skin also showed a decrease in dermal thickness.This is the first case series describing the successful application of imiquimod in the management of morphoea.

2005 British Journal of Dermatology

1766. p16ink4a expression decreases during imiquimod treatment of anal intraepithelial neoplasia in human immunodeficiency virus-infected men and correlates with the decline of lesional high-risk human papillomavirus DNA load. (Abstract)

p16ink4a expression decreases during imiquimod treatment of anal intraepithelial neoplasia in human immunodeficiency virus-infected men and correlates with the decline of lesional high-risk human papillomavirus DNA load. Human papillomavirus (HPV)-associated anogenital cancers and their precursor lesions occur in excess in human immunodeficiency virus (HIV)-infected patients despite the initiation of highly active antiretroviral therapy. In this context, a drastically increased relative risk (...) for anal intraepithelial neoplasia (AIN) exists in HIV-infected men having sex with men (MSM). In a pilot study, imiquimod, a topical immune response modifier, has been reported to be beneficial in the treatment of AIN.To investigate the role of several biomarkers as potential adjuncts in the course of imiquimod treatment for AIN, and to determine whether these markers correlate with the course of high-risk HPV DNA load during imiquimod therapy.Immunohistochemical staining was performed for p16(ink4a

2007 British Journal of Dermatology

1767. Solitary plaque mycosis fungoides on the penis responding to topical imiquimod therapy. (Abstract)

Solitary plaque mycosis fungoides on the penis responding to topical imiquimod therapy. Mycosis fungoides (MF) presenting in the genitalia is rare. We report a case of long-standing penile MF in a young man. Commonly used treatments for limited plaque MF include topical corticosteroids and ultraviolet light therapy. There are a few anecdotal reports on the use of topical imiquimod in MF. Our patient responded well and remained in complete remission after treatment with topical imiquimod.

2007 British Journal of Dermatology

1768. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Full Text available with Trip Pro

Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Surgical excision is the treatment of choice for lentigo maligna (LM), or melanoma in situ. Topical application of imiquimod, a local immune response modifier, is a novel therapeutic approach that leads to LM tumor clearance. This pilot, open-label, nonrandomized study evaluates the efficacy of imiquimod in patients with LM and other systemic problems that make them poor surgical risks.Six biopsy-proven (...) cases of LM from 5 patients (age range, 67-80 years) in whom standard surgical therapy was contraindicated were enrolled in the study. Five tumors were located on the face and 1 on the right shoulder. Imiquimod was used as a 5% cream once a day for a maximum of 13 weeks. Immediate clinical responses and follow-up, as well as histopathologic changes and immunohistologic parameters (in 2 patients), were analyzed. The complete response rate for all LM cases was 100%. Time to complete clearing varied

2005 Archives of Dermatology

1769. Giant condyloma acuminata of Buschke-Löwenstein: successful treatment with a combination of surgical excision, oral acitretin and topical imiquimod. (Abstract)

Giant condyloma acuminata of Buschke-Löwenstein: successful treatment with a combination of surgical excision, oral acitretin and topical imiquimod. Human papillomavirus (HPV) is the most common sexually transmitted disorder in young, sexually active populations in the USA and Europe. Giant condyloma acuminatum (GCA) is a unique variant of condyloma acuminata, characterized by local aggressive behaviour despite benign histology. It carries a substantial risk of squamous cell carcinoma. Various (...) treatments have been used, but response is often poor and recurrence rates high. We present a case of GCA successfully treated with a combination of surgical excision, oral acitretin and topical imiquimod. The diagnosis was based on histological examination, immunohistochemical analysis and in situ hybridization for HPV 6 and 11. We recommend a trial of oral retinoid and topical imiquimod in selected cases of GCA.

2008 Clinical & Experimental Dermatology

1770. Treatment of Classic Kaposi's Sarcoma with Topical Imiquimod. Full Text available with Trip Pro

Treatment of Classic Kaposi's Sarcoma with Topical Imiquimod. 19076206 2009 01 23 2018 12 01 1524-4725 35 1 2009 Jan Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] Dermatol Surg Treatment of classic Kaposi's sarcoma with topical imiquimod. 147-9 10.1111/j.1524-4725.2008.34397.x Goiriz Rebeca R Department of Dermatology, University Hospital, La Princesa, Madrid, Spain. rgoiriz@yahoo.es Ríos-Buceta Luis L De Arriba Ana González AG Aragüés (...) Maximiliano M García-Diez Amaro A eng Journal Article 2008 12 06 United States Dermatol Surg 9504371 1076-0512 0 Aminoquinolines 0 Antineoplastic Agents P1QW714R7M Imiquimod IM Administration, Topical Aged, 80 and over Aminoquinolines administration & dosage Antineoplastic Agents administration & dosage Humans Imiquimod Male Sarcoma, Kaposi drug therapy 2008 12 17 9 0 2008 12 17 9 0 2009 1 24 9 0 ppublish 19076206 DSU34397 10.1111/j.1524-4725.2008.34397.x

2008 Dermatologic Surgery

1771. A pharmaceutical comparison of different commercially available imiquimod 5% cream products. (Abstract)

A pharmaceutical comparison of different commercially available imiquimod 5% cream products. Alternatives to the innovator product for imiquimod 5% cream are currently marketed in South America and the People's Republic of China.Seven alternative imiquimod 5% cream products were compared with the innovator product using physiochemical tests for cream appearance, pH, drug content and presence of crystals, as well as in vitro release testing of drug using Franz diffusion cells.In contrast (...) to the innovator product, which had no crystalline imiquimod, significant amounts of suspended crystalline imiquimod were found in six of the seven alternative products. In vitro release rates of imiquimod were significantly slower in these six products compared with the innovator (p<0.001). In vitro release rates of imiquimod were significantly faster than the innovator (p<0.05) for the one alternative product without crystals.The clinical relevance of the differences observed is unknown; however, they raise

2008 Journal of Dermatological Treatment

1772. Peculiar clinical and dermoscopic remission pattern following imiquimod therapy of basal cell carcinoma in seborrhoeic areas of the face. (Abstract)

Peculiar clinical and dermoscopic remission pattern following imiquimod therapy of basal cell carcinoma in seborrhoeic areas of the face. Imiquimod is a 240.3-Da synthetic imidazoquinolinamine (C14H16N4), developed in 1983 and approved in 1997 by the US Food and Drug Administration for the topical treatment of external genital and perianal warts and, more recently, also for actinic keratosis and superficial basal cell carcinomas. We report five cases of patients affected by basal cell (...) carcinomas localized in seborrhoeic areas of the face, successfully treated with topical imiquimod and characterized by the occurrence of eruptive epidermoid cysts at the end-point of therapy. The dermatoscopic evaluation disclosed the presence in all lesions of a common feature characterized by a hyperkeratotic yellow-withish area, resembling 'popcorn', excluding dermoscopic basal cell carcinoma features. Furthermore, histological proof confirmed the diagnosis of epidermoid cysts. As reported

2008 Journal of Dermatological Treatment

1773. Imiquimod in vulvar Paget's disease: a case report. (Abstract)

Imiquimod in vulvar Paget's disease: a case report. Vulvar Paget's disease is a relatively rare gynecologic neoplasm that is problematic because of its propensity to recur.An 80-year-old woman was found to have recurrent Paget's disease of the vulva. She was initially diagnosed 12 years previously and had had multiple resections for the disease. She was found to have histologically proven Paget's disease and underwent a course of topical immune modulator therapy with imiquimod. Biopsy proved (...) histologic regression of the disease progress. The patient remained without recurrence 12 months after therapy.In select patients imiquimod may be used to treat or facilitate treatment of vulvar Paget's disease.

2008 Journal of Reproductive Medicine

1774. Pityriasis rubra pilaris exacerbation with topical use of imiquimod. (Abstract)

Pityriasis rubra pilaris exacerbation with topical use of imiquimod. The role of immune response modifiers is increasing in the treatment of dermatologic diseases. Imiquimod, a toll-like receptor agonist, results in up-regulation of proinflammatory cytokines for improved immune surveillance. Although topical use is generally well-tolerated, imiquimod can potentially result in systemic effects and exacerbate generalized inflammatory papulosquamous diseases of the skin. We report the case of a 67 (...) -year-old man who was treated with imiquimod for actinic keratosis and developed fever and a progressive erythematous papulosquamous eruption that was histologically consistent with pityriasis rubra pilaris.

2008 International Journal of Dermatology

1775. Lentigo Maligna Managed with Topical Imiquimod and Dermoscopy: Report of Two Cases. (Abstract)

Lentigo Maligna Managed with Topical Imiquimod and Dermoscopy: Report of Two Cases. 18798748 2008 12 18 2018 12 01 1524-4725 34 11 2008 Nov Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] Dermatol Surg Lentigo maligna managed with topical imiquimod and dermoscopy: report of two cases. 1561-6 10.1111/j.1524-4725.2008.34322.x de Troya-Martín Magdalena M Department of Dermatology, Hospital Costa del Sol, Marbella, Spain. magdatm@hcs.es Frieyro (...) -Elicegui Marta M Fúnez Liébana Rafael R Aguilar Bernier Miguel M Fernández-Canedo N Ines NI Blázquez Sánchez Nuria N eng Case Reports Journal Article 2008 09 15 United States Dermatol Surg 9504371 1076-0512 0 Aminoquinolines 0 Antineoplastic Agents P1QW714R7M Imiquimod IM Administration, Topical Aged, 80 and over Aminoquinolines administration & dosage Antineoplastic Agents administration & dosage Dermoscopy Female Humans Hutchinson's Melanotic Freckle drug therapy pathology Imiquimod Male Skin

2008 Dermatologic Surgery

1776. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. Full Text available with Trip Pro

Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. Imiquimod, an immune response modifier that is used topically to treat different types of skin cancer, induces the production of proinflammatory cytokines that stimulate an antitumor immune response. We assessed characteristics of the imiquimod-induced immune activation in epithelial and lymphoproliferative neoplasias of human skin. We focused on plasmacytoid predendritic cells (...) (PDCs), the primary producer of interferon alpha (IFN-alpha) after imiquimod activation in vitro.We used Affymetrix oligonucleotide arrays to compare gene expression profiles from tumors from 16 patients, 10 with superficial basal cell carcinomas (sBCCs), five with cutaneous T-cell lymphomas (CTCLs), and one with Bowen's disease, before and after topical imiquimod treatment. We used quantitative immunohistochemistry with PDC-specific antibodies against BDCA-2 and CD123 to characterize the PDC

2005 Journal of the National Cancer Institute

1777. Final results of a phase 2 study using continuous 5% Imiquimod cream application in the primary treatment of high-grade vulva intraepithelial neoplasia. (Abstract)

Final results of a phase 2 study using continuous 5% Imiquimod cream application in the primary treatment of high-grade vulva intraepithelial neoplasia. To investigate the activity of 5% Imiquimod cream in the primary treatment of vulva intraepithelial neoplasia (VIN) grade 2/3.Patients with histologically confirmed VIN 2/3 were recruited from regional colposcopy units. A Simon two-stage phase 2 study design was used. Imiquimod cream was applied over the abnormal VIN areas by the patients (...) effects being only minor skin irritation at the application site. Histologic complete response was observed in 21 patients with partial response in another nine patients. The overall response rate was 77% using intention to treat principle. No VIN progression or cancer was diagnosed. At a median follow-up of 16 months in the whole study cohort, eight recurrences (20.5%) were observed. In comparison, the recurrence rate for primary surgically treated patients was 53.5% (p=0.013).Imiquimod cream

2007 Gynecologic Oncology

1778. Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection. (Abstract)

Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection. Transcutaneous immunization (TCI) using ligands of Toll-like receptors (TLRs) and cytotoxic T-lymphocyte (CTL) epitopes lead to the induction of potent T-cell responses. To characterize the efficacy of TCI-mediated CTL activation, we monitored the frequency and functional activity of specific CTL induced with TCI using the ovalbumin-derived

2007 Clinical Reviews in Allergy & Immunology

1779. Imiquimod 5% cream in the treatment of mycosis fungoides--a pilot study. (Abstract)

Imiquimod 5% cream in the treatment of mycosis fungoides--a pilot study. 15204164 2004 07 29 2018 11 30 0954-6634 15 2 2004 Apr The Journal of dermatological treatment J Dermatolog Treat Imiquimod 5% cream in the treatment of mycosis fungoides--a pilot study. 118-9 Chong A A Loo W J WJ Banney L L Grant J W JW Norris P G PG eng Clinical Trial Letter Randomized Controlled Trial England J Dermatolog Treat 8918133 0954-6634 0 Aminoquinolines 0 Antineoplastic Agents P1QW714R7M Imiquimod IM (...) Administration, Cutaneous Adult Aminoquinolines administration & dosage Antineoplastic Agents administration & dosage Double-Blind Method Female Humans Imiquimod Male Middle Aged Mycosis Fungoides drug therapy pathology Pilot Projects Skin Neoplasms drug therapy pathology Treatment Outcome 2004 6 19 5 0 2004 7 30 5 0 2004 6 19 5 0 ppublish 15204164 10.1080/09546630310019373 59HC05A57N4CA00X

2004 The Journal of dermatological treatment Controlled trial quality: uncertain

1780. Increased frequency of dosing of imiquimod 5% cream in the treatment of external genital warts in women. (Abstract)

Increased frequency of dosing of imiquimod 5% cream in the treatment of external genital warts in women. 11818121 2002 04 09 2018 11 30 0020-7292 76 2 2002 Feb International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics Int J Gynaecol Obstet Increased frequency of dosing of imiquimod 5% cream in the treatment of external genital warts in women. 191-3 Trofatter K F KF Jr Department of Obstetrics and Gynecology (...) , The University of Tennessee Medical Center at Knoxville, Knoxville, TN, USA. kftrofatter@netscape.net Ferenczy A A Fife K H KH eng Clinical Trial Clinical Trial, Phase II Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't United States Int J Gynaecol Obstet 0210174 0020-7292 0 Adjuvants, Immunologic 0 Aminoquinolines P1QW714R7M Imiquimod IM Adjuvants, Immunologic administration & dosage Adult Aminoquinolines administration & dosage Condylomata Acuminata drug therapy Drug

2002 International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>